Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Chronic Myeloid Leukemia
DRUG: Nilotinib 150 MG [Tasigna]|DRUG: Imatinib 400mg
Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Overall survival rate in years, Overall survival rate in years, 3 years cutoff|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Cholesterol level in mg, cholesterol level in mg, 3 years cutoff|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Heart state by assessment by ECG, heart state by assessment by ECG, 3 years cutoff|Nilotinib vs imatinib in patients with newly diagnosed CML-CP: Free survival rate in years, free survival rate in years, 3 years cutoff
Study size is 100 patients in 2 arms 50 patients in nilotinib ttt 50 patients in imatinib ttt